Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00168844 · ClinicalTrials.gov registry record · Phase 3
Tiotropium / Respimat One-Year Study
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 983
- Enrollment target
NCT00168844: Completed Phase 3 study, sponsored by Boehringer Ingelheim.
NCT00168844 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 983 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (27% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00168844, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 983 participants
- Enrollment target
Study Summary
To evaluate the long term effects of treatment with two doses of Tiotropium delivered by the Respimat inhaler in patients with COPD.
Primary Outcome
Trough Forced Expiratory Volume in 1 second (FEV1)
Interventions
- OTHER Placebo
- DRUG Tiotropium Inhalation Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 983 participants |
| Start Date | 2003-01 |
| Phase | Phase 3 |
What the finished NCT00168844 record still lists
NCT00168844 is an interventional study that assigns participants to a tested intervention. The registered 983 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (27% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00168844 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00168844 about?
NCT00168844 is a clinical study titled "Tiotropium / Respimat One-Year Study". To evaluate the long term effects of treatment with two doses of Tiotropium delivered by the Respimat inhaler in patients with COPD.
What is the current status of trial NCT00168844?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 983 participants. The study started on 2003-01.
What interventions are being tested in trial NCT00168844?
The interventions under investigation include: Placebo (OTHER), Tiotropium Inhalation Solution (DRUG).
Who is sponsoring clinical trial NCT00168844?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00168844's enrollment target sits among peer trials
983 322nd of 2000 higher than 1,679 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06989437 · 982 participants · Phase 2
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
- NCT06959095 · 981 participants · Phase 3
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
- NCT06337097 · 980 participants · NA
STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy
- NCT07070232 · 980 participants · Phase 1
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia